Relationship between SP142 PD-L1 Expression and ¹⁸F-FDG Uptake in Non-Small-Cell Lung Cancer

Table 1

Univariate and multivariate analysis of the relationship between programmed death ligand-1 expression and clinicopathological characteristics of non-small-cell lung cancer.

Clinical factors	Total		PD-L1 expression				Univariate analysis		Multivariate analysis
	No.	%	Negative		Positive		OR (95% CI)	value	OR (95% CI)	value
	428	100.0	265	61.9%	163	38.1%
Age (y), median (IQR)	62 (56–68)						1.17 (0.79–1.73)	0.438
<62	194	45.3	124	63.9%	70	36.1%	Reference
≥62	234	54.7	141	60.3%	93	39.7%
Sex							2.64 (1.74–4.03)	0.000	1.19 (0.61–2.29)	0.613
Male	253	59.1	134	53.0%	119	47.0%
Female	175	40.9	131	74.9%	44	25.1%	Reference
Smoking history							2.65 (1.78–3.97)	0.000	1.22 (0.65–2.29)	0.543
Never	234	54.7	169	72.2%	65	27.8%
Former/current	194	45.3	96	49.5%	98	50.5%	Reference
Size (cm), median (IQR)	3.0 (2.4–4.1)						1.41 (0.94–2.08)	0.094
<3.0	198	46.3	131	66.2%	67	33.8%	Reference
≥3.0	230	53.7	134	58.3%	96	41.7%
Pathological stage							1.21 (1.00–1.47)	0.056
I	230	53.7	158	68.7%	72	31.3%
II	75	17.5	35	46.7%	40	53.3%
III	93	21.7	53	57.0%	40	43.0%
IV	30	7.0	19	63.3%	11	36.7%
T stage							1.20 (0.98–1.47)	0.086
T1	214	50.0	144	67.3%	70	32.7%
T2	134	31.3	77	57.5%	57	42.5%
T3	44	10.3	21	47.7%	23	52.3%
T4	36	8.4	23	63.9%	13	36.1%
Lymph node metastases							1.84 (1.21–2.81)	0.005	1.40 (0.87–2.26)	0.171
N0	302	70.6	200	66.2%	102	33.8%	Reference
N1/N2/N3	126	29.4	65	51.6%	61	48.4%
Metastatic							0.94 (0.43–2.02)	0.868
M0	398	93.0	246	61.8%	152	38.2%	Reference
M1	30	7.0	19	63.3%	11	36.7%
SUVmax, median (IQR)	9.42 (4.62–14.49)						5.15 (3.09–8.57)	0.000	2.90 (1.64–5.12)	0.000
<6.06	140	32.7	118	84.3%	22	15.7%	Reference
≥6.06	288	67.3	147	51.0%	141	49.0%
Histological subtype							3.99 (2.62–6.09)	0.000	2.12 (1.30–3.45)	0.003
ADC	319	74.5	228	71.5%	91	28.5%
SCC	95	22.2	34	35.8%	61	64.2%
Other	14	3.3	3	21.4%	11	78.6%
EGFR mutation status							3.32 (2.20–5.00)	0.000	1.60 (0.96–2.68)	0.074
Mutation	216	50.5	163	75.5%	53	24.5%	Reference
Wild type	212	49.5	102	48.1%	110	51.9%

PD-L1, programmed cell death ligand-1; SUVmax, maximum standardized uptake value; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor; IQR, interquartile range.